Ocugen, Inc. Announces Submission of Emergency Use Authorization Request to the US FDA for Investigational COVID-19 Vaccine COVAXIN™ (BBV152) for Children Ages 2-18 Years
November 05, 2021 06:38 ET
|
Ocugen
COVAXIN™ (BBV152) was recently awarded Emergency Use Listing by the World Health OrganizationPediatric EUA submission based on immuno-bridging clinical trial in children, ages 2-18, demonstrating...
Ocugen to Host Conference Call on Tuesday, November 9 at 8:30 a.m. ET to Discuss Third Quarter 2021 Financial Results and Provide Business Update
November 02, 2021 18:08 ET
|
Ocugen
MALVERN, Pa., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
October 27, 2021 06:35 ET
|
Ocugen
MALVERN, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines,...
Ocugen Inc. to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic Development Conference
October 19, 2021 08:34 ET
|
Ocugen
MALVERN, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 16, 2021 09:42 ET
|
Ocugen
MALVERN, Pa., Oct. 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen, Inc. to Participate in Fireside Chat at the Cantor Virtual Global Healthcare Conference
September 23, 2021 16:08 ET
|
Ocugen
MALVERN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 17, 2021 16:52 ET
|
Ocugen
MALVERN, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen, Inc. to Present at Upcoming Citi and H.C. Wainwright Investment Conferences
September 07, 2021 17:22 ET
|
Ocugen
MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 20, 2021 16:34 ET
|
Ocugen
MALVERN, Pa., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Provides Business Update and Second Quarter 2021 Financial Results
August 06, 2021 07:32 ET
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET Rolling regulatory submission to Health Canada completed and review process initiated; U.S. FDA talks continueMultiple milestones achieved...